CD44 and prostate carcinoma: In a prostate cancer model investigating αvβ3–OPN blockade, bisphosphonates were found to inhibit the subsequent Rho GTPase activation, thus attenuating CD44/MMP-9 binding and reducing prostate cancer cell migration [134].